$22.27
▲ +0.8% Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
UBS Adjusts Cullinan Therapeutics Price Target to $27 From $24, Maintains Buy Rating
New Taiho, Cullinan data heats up lung cancer drug battle
Wedbush Adjusts PT on Cullinan Therapeutics to $42 From $39, Maintains Outperform Rating
Overview
52-week range
$5.68
$23
95% of range
Avg surprise (last 3)
-5.8%
Avg reaction (last 2)
-0.4%
50% positive
Latest IV / EM
155%
EM ±24.2% · $22 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.75 | $-0.80 | +6.2% | -1.4% | -1.8% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | $-1.07 | $-0.83 | -28.9% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.74 | $-0.78 | +5.1% | — | +0.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.69 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.75 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.86 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.91 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.82 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-1.42 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-57M | $-54M | — | $-56M | $-76M | $-55M | — | $-49M |
| Net income | $-54M | $-50M | — | $-51M | $-70M | $-49M | — | $-41M |
| EPS (diluted) | — | — | — | — | — | — | — | $-0.69 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $79M | $75M | $88M | $103M | $73M | $77M | $83M | $102M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $342M | $361M | $387M | $342M | $276M | $318M | $415M | $592M |
| Total assets | $364M | $403M | $448M | $484M | $520M | $580M | $622M | $653M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $42M | $37M | $40M | $33M | $28M | $28M | $31M | $25M |
| Total equity | $322M | $366M | $409M | $451M | $492M | $552M | $590M | $628M |